|
Jun 23
|
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
|
|
Jun 20
|
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
|
|
Jun 19
|
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial
|
|
Jun 18
|
Why Scholar Rock Shares Are Soaring Today
|
|
Jun 18
|
Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results
|
|
Jun 18
|
Traders Eye Fed Decision, Driving Muted Premarket Action for US Equity Futures
|
|
Jun 18
|
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Announcement Amid Geopolitical Tensions
|
|
Jun 18
|
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
|
|
May 28
|
Scholar Rock to Present at the Jefferies Global Healthcare Conference
|
|
Apr 23
|
Why Scholar Rock Holding Stock Topped the Market Today
|
|
Apr 21
|
Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ...
|
|
Feb 28
|
Q4 2024 Scholar Rock Holding Corp Earnings Call
|
|
Feb 27
|
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress
|
|
Feb 24
|
Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now?
|
|
Feb 21
|
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
|
|
Feb 10
|
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
|
|
Jan 2
|
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Oct 8
|
Scholar Rock’s SMA Treatment Trials Show Promising Results
|
|
Oct 8
|
Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says
|
|
Oct 8
|
Scholar Rock stocks skyrocket after SMA drug scores at Phase III
|